<DOC>
	<DOCNO>NCT01961921</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability long-term dose ALN-TTR02 ( patisiran ) patient transthyretin ( TTR ) mediate amyloidosis ( ATTR ) .</brief_summary>
	<brief_title>The Study Investigational Drug , ALN-TTR02 ( Patisiran ) , Treatment Transthyretin ( TTR ) -Mediated Amyloidosis Patients Who Have Already Been Treated With ALN-TTR02 ( Patisiran )</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Previously receive tolerate ALNTTR02 ( patisiran ) Study ALNTTR02002 . Adequate Karnofsky performance status , liver function , renal function . Pregnant nursing . Has liver transplant . Has New York Heart Association heart failure classification &gt; 2 . Has unstable angina . Has uncontrolled clinically significant cardiac arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>